StratifAI, an AI-driven precision oncology company behind the Polaris platform, has been selected to participate in the Memorial Sloan Kettering iHub Challenge 2025 Cohort. This opportunity grants StratifAI access to MSK’s extensive clinical datasets and enables close collaboration with top clinicians and researchers. The partnership is aimed at accelerating the validation of the Polaris platform, enhancing its credibility and usefulness for oncologists globally.
Health Technology Insights: Cohere Health Launches AI Prior Authorization Tool
The collaboration seeks to create ongoing pathways for Polaris to be validated in a variety of clinical settings, broadening its application and strengthening its role in cancer care worldwide. Polaris is a fully digital, multimodal AI system that converts routine clinical data into innovative biomarkers that guide treatment decisions. Unlike traditional biomarker discovery, which can be costly and time-consuming, Polaris is designed for wide accessibility and global scalability by using data already gathered in standard clinical practice. Through MSK’s resources, StratifAI aims to further validate Polaris with real-world data as the company moves toward regulatory approval and incorporation into guidelines in both the European Union and the United States.
Health Technology Insights: Dermatology of Miami Adds Dr. George Glinos to Team
The collaboration is expected to extend beyond the iHub Challenge itself, with both StratifAI and MSK committed to long-term cooperation that supports ongoing validation efforts. Omar El Nahhas, CEO and co-founder of StratifAI, emphasized the importance of this partnership, saying that validating Polaris on thousands of MSK patient samples is a critical step toward clinical certification and inclusion in major healthcare guidelines. He also highlighted how working closely with MSK’s expert clinicians and researchers will help refine the platform and advance the company’s mission to provide high-quality cancer care globally.
Rick Peng, who manages the iHub program and leads Digital Ventures at MSK’s Office of Entrepreneurship & Commercialization, expressed excitement about welcoming StratifAI to the 2025 Cohort. He pointed out that the company stood out during a competitive selection process due to its strong focus on technology innovation and its potential to rapidly make an impact with MSK’s support.
This partnership builds on StratifAI’s existing work validating Polaris Breast, a test that assesses the risk of breast cancer recurrence in early-stage patients. By leveraging exclusive data partnerships in both Europe and the U.S., StratifAI is gathering the clinical evidence needed for regulatory approval, reimbursement, and integration into international treatment protocols.
Health Technology Insights: Town Hall Ventures Closes $440Million Fund to Boost AI Healthcare Access
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
